Phio Pharmaceuticals Corp Stock Performance
| PHIO Stock | USD 1.02 0.01 0.97% |
The company holds a Beta of 2.15, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Phio Pharmaceuticals will likely underperform. At this point, Phio Pharmaceuticals Corp has a negative expected return of -1.04%. Please make sure to check Phio Pharmaceuticals' standard deviation, treynor ratio, as well as the relationship between the Treynor Ratio and day median price , to decide if Phio Pharmaceuticals Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Phio Pharmaceuticals Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's forward indicators remain very healthy which may send shares a bit higher in March 2026. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Last Split Factor 1:9 | Dividend Date 2020-01-15 | Last Split Date 2024-07-05 |
1 | How Phio Pharmaceuticals Corp. stock reacts to fiscal policies - 2025 Earnings Impact Momentum Based Trading Ideas - newser.com | 11/10/2025 |
2 | Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | 11/13/2025 |
3 | Insider Buying Robert Bitterman Acquires Additional Shares of P - GuruFocus | 11/19/2025 |
4 | Insider Trading | 11/21/2025 |
5 | Acquisition by Dispersyn Gerrit of 350000 shares of Phio Pharmaceuticals at 0.1 subject to Rule 16b-3 | 11/28/2025 |
6 | Acquisition by Robert Bitterman of 5000 shares of Phio Pharmaceuticals at 1.02 subject to Rule 16b-3 | 12/23/2025 |
7 | Acquisition by Robert Bitterman of 5000 shares of Phio Pharmaceuticals at 1.03 subject to Rule 16b-3 | 12/31/2025 |
8 | Trend Recap How Phio Pharmaceuticals Corp stock reacts to Fed rate cuts - Quarterly Performance Summary High Win Rate Trade Tips - moha.gov.vn | 01/12/2026 |
9 | Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026 | 01/15/2026 |
10 | Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference | 01/26/2026 |
| Begin Period Cash Flow | 8.5 M | |
| Total Cashflows From Investing Activities | 8000.00 |
Phio Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 205.00 in Phio Pharmaceuticals Corp on October 31, 2025 and sell it today you would lose (103.00) from holding Phio Pharmaceuticals Corp or give up 50.24% of portfolio value over 90 days. Phio Pharmaceuticals Corp is currently does not generate positive expected returns and assumes 4.3557% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than Phio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Phio Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Phio Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.02 | 90 days | 1.02 | about 81.02 |
Based on a normal probability distribution, the odds of Phio Pharmaceuticals to move above the current price in 90 days from now is about 81.02 (This Phio Pharmaceuticals Corp probability density function shows the probability of Phio Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.15 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Phio Pharmaceuticals will likely underperform. Additionally Phio Pharmaceuticals Corp has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Phio Pharmaceuticals Price Density |
| Price |
Predictive Modules for Phio Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Phio Pharmaceuticals Corp. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Phio Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Phio Pharmaceuticals is not an exception. The market had few large corrections towards the Phio Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Phio Pharmaceuticals Corp, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Phio Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.18 | |
β | Beta against Dow Jones | 2.15 | |
σ | Overall volatility | 0.33 | |
Ir | Information ratio | -0.26 |
Phio Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Phio Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Phio Pharmaceuticals Corp can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Phio Pharmaceuticals generated a negative expected return over the last 90 days | |
| Phio Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Phio Pharmaceuticals has high historical volatility and very poor performance | |
| Phio Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (7.15 M) with loss before overhead, payroll, taxes, and interest of (3.59 M). | |
| Phio Pharmaceuticals Corp currently holds about 18.02 M in cash with (7.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Phio Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference |
Phio Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Phio Stock often depends not only on the future outlook of the current and potential Phio Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Phio Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 7.9 M | |
| Cash And Short Term Investments | 5.4 M |
Phio Pharmaceuticals Fundamentals Growth
Phio Stock prices reflect investors' perceptions of the future prospects and financial health of Phio Pharmaceuticals, and Phio Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Phio Stock performance.
| Return On Equity | -1.02 | ||||
| Return On Asset | -0.56 | ||||
| Current Valuation | 2.52 M | ||||
| Shares Outstanding | 11.04 M | ||||
| Price To Earning | (0.80) X | ||||
| Price To Book | 1.12 X | ||||
| Price To Sales | 48.01 X | ||||
| Gross Profit | (3.59 M) | ||||
| EBITDA | (7.38 M) | ||||
| Net Income | (7.15 M) | ||||
| Cash And Equivalents | 18.02 M | ||||
| Cash Per Share | 1.32 X | ||||
| Total Debt | 1.01 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.48 X | ||||
| Book Value Per Share | 2.10 X | ||||
| Cash Flow From Operations | (7.11 M) | ||||
| Earnings Per Share | (2.09) X | ||||
| Market Capitalization | 15.79 M | ||||
| Total Asset | 5.74 M | ||||
| Retained Earnings | (146.36 M) | ||||
| Working Capital | 4.72 M | ||||
| Current Asset | 9.23 M | ||||
| Current Liabilities | 2.17 M | ||||
About Phio Pharmaceuticals Performance
By examining Phio Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Phio Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Phio Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.12) | (1.18) | |
| Return On Capital Employed | (1.80) | (1.71) | |
| Return On Assets | (1.12) | (1.18) | |
| Return On Equity | (1.74) | (1.65) |
Things to note about Phio Pharmaceuticals Corp performance evaluation
Checking the ongoing alerts about Phio Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Phio Pharmaceuticals Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Phio Pharmaceuticals generated a negative expected return over the last 90 days | |
| Phio Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Phio Pharmaceuticals has high historical volatility and very poor performance | |
| Phio Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (7.15 M) with loss before overhead, payroll, taxes, and interest of (3.59 M). | |
| Phio Pharmaceuticals Corp currently holds about 18.02 M in cash with (7.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Phio Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference |
- Analyzing Phio Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Phio Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Phio Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Phio Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Phio Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Phio Pharmaceuticals' stock. These opinions can provide insight into Phio Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phio Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Will Biotechnology sector continue expanding? Could Phio diversify its offerings? Factors like these will boost the valuation of Phio Pharmaceuticals. Anticipated expansion of Phio directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Phio Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Phio Pharmaceuticals Corp's market price often diverges from its book value, the accounting figure shown on Phio's balance sheet. Smart investors calculate Phio Pharmaceuticals' intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Phio Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Phio Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Phio Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.